SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing a sharp sell-off driven by a confluence of negative sentiment, including a federal jury finding that Elon Musk defrauded Twitter shareholders and concerns regarding broader macroeconomic instability. The community is deeply divided, with bears pointing to falling delivery numbers and operational scrutiny as evidence of a structural decline, while loyal bulls continue to highlight upcoming projects like TeraFab and the potential for a rebound as reasons to maintain their positions.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors capitalize on its recent NYSE listing, which provides rare public market access to high-profile private AI and tech companies like Anthropic, OpenAI, and SpaceX. While the community is actively debating the significant premium over the fund's net asset value and the impact of a six-month lockup on available float, many are focused on the stock's high volatility and potential for momentum-driven price swings.

Coupang, Inc. engages in the provision of retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, and Farfetch. It operates through the Product Commerce and Developing Offerings segments. The Product Commerce segment consists of the company's core retail and marketplace offerings and Rocket Fresh, its fresh grocery category offering. It also includes advertising products associated with these offerings. The Developing Offerings segment covers the company's more nascent offerings and services including: Coupang Eats, a restaurant ordering and delivery service in Korea, Coupang Play, an online content streaming service in Korea, fintech services, retail operations in Taiwan, as well as advertising products associated with these offerings. It also includes Farfetch, a global luxury fashion marketplace. The company was founded by Bom Kim in 2010 and is headquartered in Seattle, WA.

Coupang Inc - Ordinary Shares - Class A

Coupang Inc 

Coupang is currently trending due to a major data breach involving approximately 33 million accounts, sparking intense regulatory scrutiny, a nationwide boycott in South Korea, and a significant leadership shake-up. Investors are actively debating the potential for long-term recovery against the backdrop of mounting legal liabilities, government investigations, and consumer backlash that threatens to disrupt the company's core market.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is experiencing significant volatility and downward pressure as investors weigh recent acquisition activity against broader macroeconomic headwinds, including geopolitical tensions and fluctuating construction market sentiment. Despite the bearish pressure, the community remains actively divided, with many long-term shareholders continuing to express confidence in CEO Brad Jacobs' consolidation strategy while others closely monitor for the next M&A catalyst or integration updates.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is trending as the market highlights the intersection of AI and decentralized infrastructure, with community discussions heavily focused on the significance of the upcoming halving event. Investors are actively debating the long-term potential of the Bittensor network's subnet model, positioning it as a foundational layer for sovereign AI.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is generating significant buzz as investors anticipate upcoming fourth-quarter earnings and critical updates regarding the clinical development of its pipeline candidate, aritinercept. The community is actively debating the company's long-term valuation, with many shareholders expressing frustration over management's communication style while simultaneously monitoring potential M&A activity within the broader biotech sector.

iShares Trust - iShares iBoxx USD Investment Grade Corporate Bond ETF

iShares iBoxx USD Investment Grade Corporate Bond ETF

The iShares iBoxx USD Investment Grade Corporate Bond ETF ($LQD) is trending as investors monitor escalating credit risks and the potential for a broad debt default wave in a rising rate environment. The community is heavily focused on the breakdown in investment-grade and high-yield bond prices, with many participants using options to hedge against further downside volatility.

Netskope, Inc. engages in the provision of cloud based security solutions. It offers business developing analytics for visibility, policy enforcement and other cloud solutions. Its products include Netskope one SASE, Netskope one SSE, cloud access security broker, next generation secure web gateway, private access, cloud firewall, SD-WAN and skopeAI. The company was founded by Sanjay Beri, Lebin Cheng, Ravishankar Ithal, and Krishna Narayanaswamy in October 2012 and is headquartered in Santa Clara, CA.

Netskope Inc. - Ordinary Shares - Class A

Netskope is attracting significant investor interest as it trades near its IPO price, with the community actively discussing potential undervaluation, strong institutional buying, and the company's critical role in AI-native cybersecurity. Despite recent price volatility and concerns surrounding lock-up expiration, many traders view the stock as a long-term acquisition target, emphasizing its solid fundamentals and growing market share in the SASE sector.

Valero Energy Corp. engages in the manufacture and marketing of transportation fuels and other petrochemical products. It operates through the following business segments: Refining, Ethanol and Renewable Diesel. The Refining segment consists of refining operations, associated marketing activities, and logistics assets that support its refining operations. The Ethanol segment includes its ethanol operations, associated marketing activities, and logistics assets that support its ethanol operations. The Renewable Diesel covers the operations of Diamond Green Diesel Holdings LLC. The company was founded in 1980 and is headquartered in San Antonio, TX.

Valero Energy Corp.

Valero Energy Corp ($VLO) is attracting significant attention as investors weigh the stock's long-term refining dominance and renewable diesel growth potential against ongoing market volatility. Community discourse remains divided, with traders closely monitoring the impact of shifting geopolitical landscapes on refining margins and whether the stock's recent price action signals a structural breakout or a consolidation phase.

ETF Opportunities Trust - T-Rex 2X Inverse MSTR Daily Target ETF

T-Rex 2X Inverse MSTR Daily Target ETF

The community is actively trading the high volatility of $MSTZ, with many traders sharing their success in utilizing it as a tactical hedge or scalp against the price action of $MSTR and broader crypto market movements. Discussions highlight a split between those treating the asset as a quick day-trading instrument to capitalize on intraday pullbacks and those holding longer-term positions, while others debate the inherent risks of leveraged products in a volatile sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The financing uses a single-asset SPV, allowing BioAtla to fund a pivotal study without a broader equity raise.</li><li>BioAtla retains majority ownership of Oz-V, keeping 65% control across solid tumor indications after the transaction closes.</li><li>Phase 3 enrollment is expected to begin in early 2026.</li></ul>Shares of BioAtla Inc. (BCAB) slipped nearly 4% in premarket trading on Wednesday after early gains faded, as investors weighed the structure of the company’s $40 million special purpose vehicle (SPV) financing to advance its lead cancer program.<h2 class="st-heading-2">SPV Deal Funds Late-Stage Trial</h2>BioAtla said the SPV transaction with GATC Health Corp. is designed to fund a registrational Phase 3 trial of ozuriftamab vedotin (Oz-V) in patients whose oropharyngeal cancer has progressed after prior treatments.&nbsp;The company will receive an initial $5 million to support general operations and trial expenses, with the remaining $35 million expected to close in the first quarter of 2026 as the study begins.Following completion, BioAtla will retain 65% ownership of Oz-V across all solid tumor indications, while the SPV, backed by Inversagen AI LLC, will hold the remaining 35%.<h2 class="st-heading-2">Investor Focus On Structure</h2>The single-asset SPV approach allows BioAtla to fund a pivotal trial without a broader equity raise, but the structure appeared to draw a cautious response from investors after the initial premarket rally. Under the arrangement, the SPV will share in future development and commercialization economics for Oz-V.<h2 class="st-heading-2">Phase 3 Path&nbsp;</h2>BioAtla will lead execution of the Phase 3 study, with patient enrollment expected to begin in early 2026.&nbsp;The company said the trial is intended to support a potential accelerated approval pathway in the U.S. Oz-V has received Fast Track designation from the FDA for recurrent or metastatic squamous cell carcinoma of the head and neck.<h2 class="st-heading-2">BioAtla Retains Lead Role On Oz-V</h2>The company said the financing provides a near-term path to advance Oz-V while preserving majority ownership, and noted ongoing discussions around expanding the drug’s use into other HPV-positive solid tumors, including cervical cancer.&nbsp;BioAtla and GATC Health also expect to collaborate with Inversagen AI on additional research tied to senescence and longevity technologies, with BioAtla retaining rights for cancer applications.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for BioAtla was ‘bearish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:973/141;" src="https://news.stocktwits-cdn.com/bcab_ss_png_1ab7393b71.webp" alt="bcab ss.png" width="973" height="141"><figcaption>BCAB sentiment and message volume as of December 31| Source: Stocktwits</figcaption></figure>One user said the market had yet to fully price in the $40 million upfront component of the deal.<stembedurl>https://stocktwits.com/BiotechValues/message/640486061</stembedurl>Another user said the deal fell short of a true global license agreement, pointing instead to the SPV structure and its terms.<stembedurl>https://stocktwits.com/SDBiotechInvestor/message/640485518</stembedurl><a href="https://stocktwits.com/symbol/BCAB">BioAtla’s stock</a> has risen 21% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioAtla logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial

The company disclosed the terms and timeline of an SPV arrangement tied to its Oz-V development program.

Equity

Big short fame Michael Burry-run Scion Asset Management’s September quarter 13F <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1649339/000090514824003106/xslForm13F_X02/informationtable.xml">report</a> filed late Thursday showed increased exposure to its China stock holdings Alibaba Group Holding Ltd. (<a class="mention" data-mention="$BABA" data-symbol-id="BABA" href="https://stocktwits.com/symbol/BABA" target="_blank">$BABA</a>), Baidu, Inc. (<a class="mention" data-mention="$BIDU" data-symbol-id="BIDU" href="https://stocktwits.com/symbol/BIDU" target="_blank">$BIDU</a>) and JD.com. Inc. (<a class="mention" data-mention="$JD" data-symbol-id="JD" href="https://stocktwits.com/symbol/JD" target="_blank">$JD</a>). The hedge-fund manager, however, covered much of his positions in these stocks with put options.&nbsp;Burry is known for accurately predicting the 2007 subprime mortgage crisis that later morphed into the global financial crisis.At the end of the third quarter, Scion held 200,000 Alibaba ADRs valued at $21.22 million, up from 155,000 ADRs worth $11.16 million at the end of the second quarter.He hedged his Alibaba bet by buying put options on 168,900 ADRs. This strategy insulates him against any potential drop in Alibaba shares.&nbsp;Alibaba shares have rebounded nicely this year amid China’s concerted efforts to stimulate domestic growth. The e-commerce giant is scheduled to report its second-quarter results before the market opens on Friday.Burry’s firm increased its Baidu holding from 75,000 ADRs, valued at $6.49 million, to 125,000 ADRs worth $13.16 million. It also bought put options on 83,000 Baidu ADRs.The firm loaded up ADRs of Alibaba’s peer JD, increasing its stake in the company from 250,000 ADRs to 500,000 ADRs. The value of JD,com holdings swelled from $6.46 million to $20 million. Bury also bought puts on JD.com for 500,000 in underlying shares.On the other hand, Burry halved RealReal, Inc. (<a class="mention" data-mention="$REAL" data-symbol-id="REAL" href="https://stocktwits.com/symbol/REAL" target="_blank">$REAL</a>) holdings from 1 million shares to 500,00 shares. It also significantly cut its stake in&nbsp;American Coastal Insurance Corporation (<a class="mention" data-mention="$ACIC" data-symbol-id="ACIC" href="https://stocktwits.com/symbol/ACIC" target="_blank">$ACIC</a>) from 251,892 to 100,000.Scion fully cashed out of oncology-focused biotech BioAtla, Inc. (<a class="mention" data-mention="$BCAB" data-symbol-id="BCAB" href="https://stocktwits.com/symbol/BCAB" target="_blank">$BCAB</a>) and office real estate investment trust Hudson Pacific Properties, Inc. (<a class="mention" data-mention="$HPP" data-symbol-id="HPP" href="https://stocktwits.com/symbol/HPP" target="_blank">$HPP</a>).On Stocktwits, sentiment towards Burry’s China holdings is muted.&nbsp;Sentiment toward Alibaba was 'neutral' on Stocktwits platform, although improving from a 'bearish' stance a day ago.<figure class="image"><a href="https://stocktwits.com/symbol/BABA"><img style="aspect-ratio:632/133;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/baba_bury_sentiment_76d1568b0e.png" alt="baba-bury-sentiment.png" width="632" height="133"></a><figcaption>BABA sentiment and message volume November 15, 2024 premarket as of 4:06 am ET | Source:&nbsp;Stocktwits</figcaption></figure>&nbsp;JD.com elicited 'bearish sentiment' (36/100) from the retail, although message activity remained 'extremely high,' possibly due to the earnings report released Thursday.<figure class="image"><a href="https://stocktwits.com/symbol/JD"><img style="aspect-ratio:630/135;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/jd_sentiment_cffa43fe76.png" alt="jd-sentiment.png" width="630" height="135"></a><figcaption>JD sentiment and message volume November 15, 2024 premarket as of 4:06 am ET | Source:&nbsp;Stocktwits</figcaption></figure>Baidu did not fare any better, with the retail mood 'bearish' (45/100) on Stocktwits, although message volume, a proxy for activity, was 'high.'<figure class="image"><a href="https://stocktwits.com/symbol/BIDU"><img style="aspect-ratio:632/140;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/bidu_sentiment_fb301f5932.png" alt="bidu-sentiment.png" width="632" height="140"></a><figcaption>BIDU sentiment and message volume November 15, 2024 premarket as of 4:06 am ET | Source:&nbsp;Stocktwits</figcaption></figure>As of 4:06 am ET, Alibaba shares eased 0.63% to $90.01, while JD.com climbed 1.83% to $33.96 and Baidu gained 1.18% to $85.05.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/warren-buffett-s-berkshire-initiates-positions-in-domino-s-pizza-pool-corp-does-retail-share-the-sentiment/cJ4F7DqRfp">Warren Buffett’s Berkshire Initiates Positions In Domino’s Pizza, Pool Corp: Does Retail Share The Sentiment?</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

Chinese stocks are seeing green shoots of recovery amid stimulus measures to reinvigorate growth.

Michael Burry Cautiously Ups Alibaba, JD.com, Baidu Bets With Offsetting Hedges: Retail Doesn’t Share Big Short Investor’s Optimism

Burry is known for accurately predicting the 2007 subprime mortgage crisis that later morphed into the global financial crisis.

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Current Price	$0.1686
Prev Close	$0.1563
Open	$0.157
Dividend Yield	0.00%
50-Day Moving Average	$0.2269
Beta	1.74
Avg. Volume	3.07M
PE Ratio	-0.15

52-Week High	$1.43
52-Week Low	$0.13
Market Capitalization	$12.52M
EPS (Annual)	-$1.44
Price to Book	-0.32
Revenue Per Employee	$144,736.84

BCAB
BioAtla Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCAB News

BCABBioAtla Inc